Chapter 4
EpCAM in carcinogenesis: the good, the bad or the ugly 
Introduction
The epithelial cell adhesion molecule (EpCAM; CD326) is a transmembrane glycoprotein originally discovered on colon carcinomas 184 . EpCAM is expressed by the epithelium of healthy individuals, except by squamous epithelium, and some specific epithelial cell types, such as hepatocytes and keratinocytes 185 , but in most human carcinomas, EpCAM is overexpressed to varying degrees 186 . The diagnostic and prognostic characteristics of EpCAM have been demonstrated by many independent research groups 186,187 and the EpCAM overexpression is exploited in several EpCAM directed antibody-or vaccine-based clinical trials for a wide variety of carcinomas 188 . Recently, EpCAM has been identified as an additional marker for cancer-initiating stem cells 189 , which makes it an even more interesting target for cancer therapy. Several biological functions of EpCAM have been described: EpCAM is able to abrogate E-cadherin-mediated cell-cell adhesion by disrupting the link between a-catenin and F-actin thereby loosening cell-cell adhesion 72 . In addition, association of EpCAM with claudin-7 interferes with EpCAM-mediated homotypic cell-cell adhesion, promoting cell motility, proliferation, survival, carcinogenesis and metastasis formation
73
. Furthermore, it has been shown that upon intramembrane proteolysis of EpCAM, the intracellular domain functions as part of a transcriptional complex inducing c-myc and cyclin A and E expression 190 . These findings support a role for Ep-CAM as an oncogene. Indeed, EpCAM overexpression is associated with decreased overall survival of patients with different types of cancer [191] [192] [193] [194] (see EpCAM: the Bad). In contrast to its promoting role regarding tumour formation, EpCAM is also described as a tumour suppressive protein. EpCAM was first proposed to function as a cell adhesion molecule since EpCAM is able to mediate homophilic adhesive interactions 195 , thereby preventing cell scattering. Due to these adhesive properties, EpCAM is likely to play a role in inhibition of invasion 195, 196 . Indeed, loss of EpCAM contributed to increased migratory potential 197 and EpCAM expression on metastases was lower compared with primary tumours 198 . Moreover, EpCAM overexpression in some carcinoma types is associated with improved patient survival [199] [200] [201] [202] [203] (see EpCAM: the Good). The dual role of EpCAM is also reflected by mechanistic studies investigating the role of EpCAM by enforced modulation of EpCAM expression. Murine colorectal carcinoma cells transfected with murine EpCAM complementary DNA (cDNA) increased cell-cell adhesion, attenuated tumour cell invasion in matrigel and decreased tumour incidence and metastasis when inoculated in the spleen of the mice
196
. These data suggest that EpCAM expression antagonizes tumour growth and metastasis. In contrast, induction of EpCAM expression into human embryonic kidney cells (HEK293) as well as into murine fibroblasts showed an enhanced metabolism and colony formation capacity compared with the empty vector-transfected cells
204
. Furthermore, in four different carcinoma types, forced downregulation of EpCAM expression utilizing antisense or small interfering RNA (siRNA) decreased cell proliferation, migration and invasiveness 69, [204] [205] [206] [207] . Whether EpCAM acts as a tumour suppressive gene or as an oncogene might depend on the microenvironment. Since epigenetic regulation is associated with aberrant EpCAM expression, recent advances in epigenetic interference 208,209 might be a promising novel approach to either
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half LIM domain protein 2), b-catenin and the transcription factor Lef-1. This transcription complex binds the DNA at the Lef-1 consensus sites inducing c-myc and cyclin A and E expression
190
. The oncogenic potential of EpICD was demonstrated in a mouse xenograft model, in which HEK293 cells stably expressing EpCAM or EpICD produced nearly equivalent large tumours, whereas control cells only formed a small tumour in a single case
. Interestingly, EpCAM has also been identified as a marker for cancer-initiating stem cells for several carcinoma types: EpCAM expressing pancreatic cancer stem cells showed a 100-fold enhanced tumourigenic potential compared with EpCAM-negative pancreatic cancer stem cells
219
. Also, EpCAM-positive hepatocellular carcinoma stem cells, but not EpCAM-negative hepatocellular carcinoma stem cells, could efficiently initiate tumours in severe combined immunodeficient mice
207
. Also for breast cancer stem cells, the ability to form tumours in nonobese diabetic/severe combined immunodeficient mice was for EpCAM-positive cells 50-fold greater compared with the unfractioned tumour cells
220
. Although both EpCAM negative and EpCAM-positive cancer stem cells were able to form tumours, 10-fold less EpCAM-positive cells than EpCAM-negative cells were able to induce tumours. Based on the above and on the application of EpCAM as a therapeutic immune target, it is clear that EpCAM is an important player in carcinogenesis; however, the exact biological roles are not clear. In some carcinoma types, EpCAM is the 'good guy', being associated with improved survival, whereas in other carcinoma types, EpCAM is the 'bad guy' being associated with decreased survival. Interestingly, for several types of carcinoma both roles have been reported, which makes EpCAM an 'ugly player' for the clinical setting.
EpCAM: the Good?
The name EpCAM reflects its function as a homophilic intercellular adhesion molecule as demonstrated by Litvinov et al. 195 . From this, one might expect EpCAM to prevent metastases and as such acting as a good guy. However, only for two tumour types, high EpCAM expression has been consistently associated with improved clinical outcome. In metastases of renal clear cell carcinomas, EpCAM was less frequently expressed than in primaries 198 and high EpCAM expression in the primary was associated with improved patient survival 202, 221 . Similarly, in thyroid carcinoma, EpCAM expression was lower in less differentiated tumours and high expression correlated with improved survival 199, 222 . Downregulation of EpCAM in these tumours might reflect general tumour dedifferentiation, rather than a functional downregulation for EMT. However, the recent study by Ralhan et al. 222 indicates that loss of membranous EpCAM in anaplastic (undifferentiated) thyroid carcinoma might be due to cleavage of EpCAM. More details of these studies are presented in 
Biological role of EpCAM in carcinogenesis
The highly overexpressed tumour-associated antigen on most carcinomas, currently referred to as EpCAM, has been 'discovered' multiple times 188 .With each discovery, EpCAM received the name of the respective monoclonal antibody or cDNA clone, leading to many synonyms including epithelial glycoprotein-2 (EGP-2), epithelialspecific antigen (ESA), GA733-2 and tumour-associated calcium signal transducer 1 (TACSTD1)
188 . EpCAM localizes to the basolateral membrane in normal epithelial tissue, but in carcinoma, this expression pattern changes to an intense uniform membranous overexpression, frequently also associated with cytoplasmic staining 69, 197 . In addition, EpCAM was found to be hyperglycosylated in carcinoma tissue as compared with healthy autologous epithelia 210, 211 . EpCAM is a transmembrane protein consisting of an extracellular domain (EpEX), a single transmembrane domain and a short 26-amino acid intracellular domain (EpICD)
188
. The extracellular domain comprises an epidermal growth factor-like domain, a thyroglobulin repeat domain followed by a cysteine-poor domain. The epidermal growth factor-like and thyroglobulin domains form a globular structure and are required for the homophilic cell-cell adhesion of EpCAM
212
. It has been suggested that the adhesive properties of EpCAM might prevent metastasis because intercellular adhesion should be reduced to gain the ability to migrate. Metastasis involves loss of cell-cell adhesion and cell polarity, an increase in cell motility and invasion. Development of such a mesenchymal phenotype is known as epithelial mesenchymal transition (EMT) 213 and seems to require downregulation of EpCAM followed by re-expression at the site of the future metastasis. Indeed, EpCAM downregulation has been associated with EMT 214,215 and in mice with colon carcinoma, small metastases were EpCAM negative but large metastases in the same mouse displayed an equal level of expression as the primary
216
, possibly reflecting the re-expression at the metastatic site. In line with these findings, one log reduction in EpCAM expression on circulating tumour cells was found compared with various primary tumours and their metastases 217 . However, EpCAM-mediated homotypic cell-cell adhesion is influenced by association with the tight-junction protein claudin-7. Complex formation of EpCAM, claudin-7, the variant isoform of the cell-matrix adhesion protein CD44v6 and the tetraspanin CO-029, recruited into tetraspanin-enriched membrane microdomains, has been shown to facilitate metastasis formation 218 . EpCAM is also capable of abrogating the E-cadherin-mediated adhesions and to rearrange the cytoskeleton of the cell 72 . Recently, EpCAM was identified as a signal transducer
190
: regulated intramembrane proteolysis by tumor necrosis factor-a-converting enzyme cleaves EpEX, and EpICD is cleaved by presenilin-2. EpICD associates with the adaptor protein FHL2 (four and a tric cancer, Du et al. reported that EpCAM expression was associated with nodal metastasis and higher EpCAM expression showed an increase in the proliferating cell nuclear antigen. Survival was not analysed here 205, 235 , but in a different study EpCAM-positive disseminated tumour cells in pathological tumourfree lymph nodes were an independent prognostic factor for reduced survival
236
. Yet, other studies found no significant relations with expression 228, 237 . However, a protective role for EpCAM was reported by Songun et al.
203
: patients with high EpCAM In the prostate, EpCAM expression was significantly increased from normal via prostatic intraepithelial neoplasia to adenocarcinoma, but expression in adenocarcinoma was not associated with differentiation grade or clinical outcome 228, 229 . Interestingly, hormone refractory carcinomas were found to express EpCAM in a significantly higher frequency than untreated carcinomas 186 , but this finding was not confirmed in another study
.
In squamous cell carcinoma (SCC) of the lung, high EpCAM expression was associated with nodal metastasis, high-stage disease and poor differentiation
231
. A more recent study found only a trend towards a shorter survival in patients with high EpCAM expression 228 . In patients with adenocarcinoma of the lung, no clear correlations of EpCAM expression with cancer progression, metastasis or survival have been found 228, 232 . Although, EpCAM has been shown to be an accurate diagnostic marker for reverse transcription-polymerase chain reaction-based identification of lymph node micrometastasis and the presence of EpCAM-positive tumour cells in lymph nodes correlated with reduced survival rates 233, 234 . The lack of a clear effect of EpCAM on survival in lung carcinoma might reflect different effects of EpCAM in various treatment subgroups. Subgroup analysis, as performed for breast carcinoma, might provide more insights. For many other tumour types, high EpCAM expression has been associated with poor prognosis, but contradictory reports underline a dual role of EpCAM. In these tumour types for which both protecting and promoting roles for EpCAM have been described, we consider EpCAM to be an ugly player.
EpCAM: the Ugly? For several tumour types, the reported role of EpCAM seems contradictory (table 4.3). In gas- . Interestingly, this finding was associated with nuclear localization of b-catenin, consistent with the signal transducer function of EpCAM. However, a significant positive correlation of EpCAM expression with survival has only been found in a subgroup of moderately differentiated colon cancers 228 . The interaction of EpCAM with the cell-matrix adhesion molecule CD44v6 and the tight junction molecule claudin-7 in association with the tetraspanin CO-029 in tetraspanin-enriched membrane microdomains was initially found in CRC. Co-expression and complex formation of EpCAM and its partners (but not EpCAM alone) in liver metastases was accompanied by a significantly decreased disease free survival 218 . Independently, CD44 and EpCAM were identified as markers of a subpopulation with greatly enhanced tumourigenicity in a human CRC-mouse xenograft 238 . In addition, EpCAM proved to be a good marker for reverse transcription-polymerase chain reaction-based detection of CRC metastases in lymph nodes 239 .
In specimens of head and neck squamous cell carcinoma (HNSCC), EpCAM messenger RNA (mRNA) expression increased from hyperplasia via dysplasia to tumour, which might suggest a role for EpCAM in carcinogenesis
240
. EpCAM was also identified as a very good reverse transcription-polymerase chain reaction marker to detect micrometastases in lymph nodes 241 and disseminated HNSCC cells
242
. EpCAM is expressed de novo in HNSCC, but most studies do not find any relation with clinicopathologic variables, including differentiation and survival 70, 71, 243, 244 . However, in a study looking specifically at tongue SCC, EpCAM expression was associated with larger tumour size, nodal metastasis and tumour dedifferentiation
69
. Interestingly, recently in a Taiwanese series of oral SCC, EpCAM expression was reported to decrease from normal via dysplasia to carcinoma, and lower EpCAM labeling index was associated with, among others, larger tumour size and presence of nodal metastasis
200
. These adverse findings might be due to the large number of areca quid chewers in Taiwan. Areca quid has been shown to increase tumor necrosis factor-a production 245 and therefore might downregulate EpCAM
246
. Additionally, the article also shows nuclear expression and staining of macrophages, which has not been shown in other studies using the same antibody 70, 186 . In general, a lack of consistent association of EpCAM expression in HNSCC might be attributable to the heterogeneity of tumours included in these studies
.
In a group of esophageal cancer (mainly SCC) patients, high EpCAM expression indicated a significantly higher survival rate
201
. In contrast, Stoecklein et al. 248 identified high EpCAM as an independent prognostic factor for decreased survival. Others found no correlations with grade, stage or disease-specific survival
187
. Furthermore, the presence of EpCAM-positive cells in pathological tumour-free lymph nodes was an independent indicator for a poor prognosis
.
In epithelial ovarian cancer, EpCAM is highly overexpressed compared with normal ovarian surface epithelium and no differences in EpCAM expression were observed among different histological subtypes and grades in two independent studies. In one of these studies, with al- , indicating a promoting role for EpCAM in HNSCC. The above forced modulation studies suggest that EpCAM, whether it is a good or a bad guy for a given tumour, can serve as a therapeutic target for upregulation (good guy) or downregulation (bad guy).
To better understand why EpCAM is overexpressed in carcinomas, more insights in the regulation of the epcam gene itself are required; therefore the (epi)genetic events involved in EpCAM regulation will now be described.
Genetics
The EpCAM protein is encoded by the TACSTD1 gene originally reported as the GA733-2 gene . No splicing variants were found, although a large number of carcinoma cell lines were screened 212 . To our knowledge, mutations in the epcam gene have only been identified in patients suffering from Lynch syndrome or congenital tufting enteropathy. In Lynch syndrome, different heterozygous germ line deletions disrupt the 3'-end of the epcam gene and lead to inactivation of the adjacent MSH2 gene through methylation induction of its promoter in tissues expressing EpCAM
260
. In congenital tufting enteropathy, four different point mutations have been described resulting in decreased or no expression of EpCAM on protein level [261] [262] [263] . The EpCAM promoter region that controls the expression of the gene has been cloned and characterized [264] [265] [266] . The sequence upstream of the transcription start site (TSS) has been defined 266 (NCBI: AY148099). A 3.4 kb fragment of this EpCAM 5'-regulatory sequence is capable of directing heterologous gene expression and the promoter activity is restricted to EpCAM-expressing cells 266, 267 . A complementary study confirmed that the transcriptional activity of a 1.1 kb EpCAM fragment starting 770 bp upstream of the TSS directly correlated with the amount of EpCAM expression 265 . In silico analysis of the EpCAM promoter revealed several homologies to known that a higher expression of EpCAM correlates with tumour progression, but no correlation with relapse-free survival or disease-specific survival was found 251 . A more recent study without borderline tumours did find differences among histological subtypes and a significantly higher Ep-CAM expression in poorly differentiated tumours and overexpression correlated with decreased overall survival 252 . In a study that also looked into the expression in metastastatic and recurrent disease, these tumours were found to express significantly higher levels of EpCAM compared with primaries 253 . Studies regarding the expression of EpCAM suffer from the use of different antibodies, scoring methods and heterogeneous groups of tumours analyzed, which might lead to differing, possibly even contrasting results. Even when consistent results have been found, interpretation is not straightforward, as for example loss of EpCAM might be due to active downregulation during EMT or an effect of general tumour dedifferentiation. Nevertheless, it is quite clear that EpCAM plays a role in carcinogenesis, tumour progression and metastasis in various carcinoma types, providing opportunities for diagnosis and therapeutic interventions.
Modulation of EpCAM expression to address the biological role of EpCAM
The function of EpCAM as an adhesion molecule was discovered by induction of EpCAM in nonEpCAM-expressing cells , which reflects the correlation between high EpCAM expression and poor prognosis in breast cancer patients. In agreement with its promoting role in patients with hepatocellular carcinoma and SCC of the tongue, siRNA-mediated EpCAM reduction in cell lines decreased the invasion potential and proliferation of the cancer cells 69, 207, 255 .
the EpCAM promoter, supported a direct role for NF-kB as a repressor of the EpCAM promoter. A second repressor of EpCAM promoter activity is the tumour suppressor gene p53
268
. Induction of wild-type p53 (WT p53) was associated with a dose-dependent decrease in EpCAM expression, whereas ablation of p53 expression was associated with an increase in EpCAM expression. Ten putative binding sites for p53 in the epcam gene were identified and by chromatin immunoprecipitation, the binding of WT p53 to a site located within intron 4 was confirmed
. Interestingly, simultaneous silencing of p53 and EpCAM expression via stable transduction of short hairpin RNA prevented the increase of EpCAM expression caused by ablation of p53 expression and decreased the invasiveness of the breast cancer cells 268 .
Epigenetics
Accessibility of transcription factors to the specific binding sites within the epcam gene depends on the chromatin structure, which is affected by DNA methylation and histone modifications 270 .
Modifications of DNA and histones thus have profound impact on gene expression. Here, we will focus on DNA methylation and histone modifications, also because these epigenetic events are potentially reversible by drug treatments. DNA methylation. Already in 1994, it was described that DNA methylation prevents amplification of the epcam gene In humans, DNA methylation occurs mainly on cytosines within cytosine-guanine dinucleotides (CpGs). CpGs are relatively rare in the genome but tend to cluster in islands which are usually located in the 5'-regulatory region of many genes. Methylation of CpG islands in promoters leads to transcriptional silencing of genes. Several studies have reported that EpCAM expression is associated with DNA methylation 71, 254, [273] [274] [275] (table 4 .4). In cell lines of different origin, high EpCAM expression was associated with hypomethylation and no EpCAM expression was associated with hypermethylation of the proximal promoter and part of exon 1 275 . Interestingly, the CpG within the putative binding site for Sp1 (-231) was methylated in EpCAM-negative cell lines and not methylated in EpCAM-positive cell lines, whereas around the putative binding site for activator protein 1 (-125), the CpGs were unmethylated in all cell lines analysed 274 . Modulation by epigenetic drugs confirmed the correlation between EpCAM expression and the DNA methylation status of the epcam gene. Treatment of EpCAM-negative cell lines with a DNA demethylating agent (5-aza-2'-deoxycytidine) induced EpCAM expression de novo, both on mRNA and protein level and caused upregulation of EpCAM expression in EpCAM-positive cell lines 254, 273, 275 . However, in the EpCAM-negative leukaemia K562 (hypermethylated) and the liver HepG2 (CpGs were 50% methylated) cell lines, no EpCAM re-expression was observed after 5-aza treatment, although most methylated CpGs were converted to unmethylated CpGs
.
In addition, upon 5-aza treatment of the EpCAM-negative lung carcinoma cell line GLC-1, of which part of the epcam gene (-830 to +282) is intermediated methylated, no de novo induction of EpCAM expression was detected 275 . Alternatively, we demonstrated that endogenous transcriptional regulatory sequences and putative transcription-binding sites
266
. Although no TATA or CAAT boxes were found, the position of the consensus initiator element (Inr) matches with the putative TSS based on 5'-untranslated region sequencing studies 256, 266 . By deletion analysis, it was established that 177 bp of the 5'-flanking sequence are sufficient to drive reporter gene expression, whereas the region 687-341 bp upstream of the TSS appeared to be responsible for epithelial-specific expression The transcription factors nuclear factor-kappaB (NF-kB) and p53 have been described as transcriptional repressors of the epcam gene: treatment of EpCAM-positive SCCs with tumor necrosis factor-a and interferon alpha resulted in a reduced endogenous EpCAM expression 246, 264 . Inhibition of the activation of NF-kB by cotransfection of a plasmid coding for the dominantnegative NF-kB-inhibiting inhibitor-I-kappaB and a luciferase reporter plasmid under control of the location of the tested CpGs as well as the tissue type, appears to be of importance. Histone modifications. The nucleosome consists of an octamer of the four histone proteins (H2A, H2B, H3 and H4) wrapped around by ~147 bp of DNA. The histones are subjected to a variety of posttranslational modifications including phosphorylation, acetylation, ubiquitylation and methylation. Histone modifications play important roles in chromatin structure and function. With regard to transcriptional regulation, increases in histone acetylation and trimethylation of lysine 4 of histone 3 (H3K4me3) are generally associated with increased gene expression, whereas decreased acetylation and methylation of lysine 9 of histone 3 (H3K9me3) are marks of decreased gene expression
.
The indirect effect of histone acetylation on EpCAM expression has been demonstrated by treating carcinoma cell lines with trichostatin A, a histone deacetylase inhibitor 254 . Minimally elevated EpCAM expression was observed after trichostatin A treatment, but an increased Ep-CAM expression was induced by concomitant treatment with 5-aza, showing that both histone modification and DNA methylation are responsible for EpCAM gene expression. Compared with DNA methylation, less is known about the histone modifications characteristic for EpCAM expression. To our knowledge, only one study reports on enzymes and histone modifications involved in epigenetic regulation of the EpCAM gene 254 . In this study, chromatin immunoprecipitation revealed that association of repressive epigenetic marks (heterochromatin protein 1, the H3K9 methyltransferase SUV39H1, histone deactylase HDAC1 and the DNA methyltransferases DNMT1 and 3b) with the EpCAM promoter increased gradually as EpCAM expression in three lung adenocarcinoma cell lines decreased 254 . In agreement with their findings concerning SUV39H1 and HDAC1, acetylated H3K9 was associated with the EpCAM promoter in EpCAM-positive cell lines, whereas methylated H3K9 was associated with the EpCAM promoter in EpCAM-negative cells 254 (table 4. 
Modulation of EpCAM by epigenetic editing
Although the exact biological role of EpCAM is not clear, yet the growth inhibitory effect of Ep-CAM overexpression or silencing is established for a list of different tumour types. For such types, modulation of EpCAM expression provides a promising approach to interfere with the oncogenic potential of these tumour cells. Since the aberrant expression of EpCAM on carcinomas seems to be associated with epigenetic mutations without underlying genetic defects, modulation of EpCAM expression by epigenetic interference opens up new possibilities to modify expression levels. Unlike genetic mutations, epigenetic mutations are reversible. The reversible nature of epigenetic mutations is currently exploited by genome-wide epigenetic drugs, for example to re-express tumour suppressor genes. In epigenetic editing, molecular epigenetic marks (DNA methylation, post-translational histone modifications) are overwritten by targeting an epigenetic effector domain to the gene of interest using a sequence specific DNA-binding motif. Three classes of DNA-binding motifs are easily available to direct attached epigenetic effector domains to a specific sequence
277
. These moEpCAM expression can be actively downregulated in a persistent manner via induced DNA methylation 275 . After delivery of the DNA methyltransferase M.SssI into EpCAM-positive ovarian carcinoma cells, methylation of the epcam gene resulted in reduced EpCAM expression, which maintained through successive cell divisions as the reduced EpCAM expression persisted for at least 17 days 275 . The association between DNA methylation of the epcam gene and EpCAM expression in patient samples appears to depend on the tissue type (table 4.4). In normal colon tissues, 50% of the tested CpGs were methylated, whereas in colon cancer tissues, most CpGs were unmethylated
274
. The expression level of EpCAM was 1000-fold higher in colon cancers than in normal colon tissue, reflecting the observed methylation status. Also in lung adenocarcinoma tissue 254 and in oral squamous cell carcinoma 71 , EpCAM expression was significantly associated with the methylation status of the EpCAM promoter. In contrast, in breast cancer tissue, no correlation was found between EpCAM protein expression and EpCAM promoter methylation for six CpGs measured 273 . However, in the same study, they found the promoter of EpCAM-negative breast cancer cell line to be methylated to a higher degree as compared with an EpCAM-positive cell line. The discrepancy found between breast cancer cell lines versus tissue might be due to the number of CpGs analysed: MethyLight technology analysing six CpGs and bisulfite sequencing analysing 64 CpGs, respectively (table 4.4). Since in lung adenocarcinoma as well as in oral squamous cell carcinoma tissue, high EpCAM expression indeed correlated with a low DNA methylation level, of membrane EpEX was accompanied by increased cytoplasmic and nuclear EpICD and nuclear b-catenin localization 222 . Moreover, both loss of membranous EpEX as well as the presence of nuclear EpICD correlated with reduced patient survival. To our knowledge, this is the first study on a series of patient material showing the nuclear presence of EpICD. This finding suggests that the loss of membranous EpCAM expression as also observed in another thyroid carcinoma study 199 might be due to cleavage more than functional downregulation of EpCAM as proposed in EMT. On the other hand, proteolysis of EpCAM could also explain the association of high EpCAM expression with poor survival. It has been suggested that EpICD in its transcription complex might induce EpCAM transcription via binding of Lef to the EpCAM promoter 190, 255 . Proteolysis of EpCAM induces shedding of EpEX followed by increased nuclear EpICD, which in turn might increase EpCAM expression. However, it is not clear why re-expression of membranous EpCAM appears not to take place in thyroid cancer, which directs to a tumour type dependent role for EpCAM. In addition to taking EpICD into account, analysis for concomitant presence of claudin 7 73 , CO-029, CD44v6 and EpCAM expression might give more information regarding patient survival, since not the solitary expression, but the presence of all four molecules in a complex formation has been shown to facilitate metastasis 218 . Future clinicopathologic studies assessing co-expression of EpCAM in combination with its partners and nuclear EpICD staining may solve the ugly role of EpCAM in cancer. In this review, we classified the tumour types for which EpCAM acts as potential diagnostic marker with some prognostic significance 187 . EpCAM functions as a target in antibody-based clinical trials and in 2009, the European Medicines Agency approved the use of trifunctional bispecific antibody catumaxomab, which binds to EpCAM and enhances the immunological response against EpCAM-positive cells in malignant ascites 285 . The emerging function of Ep-CAM in cell proliferation, migration and possibly cancer initiation 284 broadens the interest to use EpCAM not only as an immunotarget but also as a target for epigenetic silencing. Cancer stem cells expressing EpCAM are more tumourigenic than EpCAM-negative stem cells 286 and because cancer stem cells are radiation and drug resistant, targeting EpCAM might be a promising approach to stop tumour initiation and progression. Since epigenetic dysregulation seems to underly aberrant EpCAM expression, epigenetic editing provides unique tools to elucidate the promoting or protective role of EpCAM by upregulate or downregulate EpCAM expression.
